Massive hope for pancreatic cancer pill after trial saw tumours vanish
Summary
Daraxonrasib, a daily pill given with chemotherapy, showed promising results in an early trial involving 61 people with advanced pancreatic cancer. Tumours stopped growing in 90% of participants, and scans showed no detectable cancer in about 8%; researchers say longer studies are needed to learn whether the treatment extends survival or keeps cancer from returning.Key Facts
- The trial included 61 patients whose pancreatic cancer had spread to other parts of the body.
- Researchers followed patients for an average of about 18 months.
- Tumours shrank or disappeared in just over 60% of participants.
- Cancer became undetectable on CT scans in about 8% of participants.
- Daraxonrasib is a KRAS inhibitor, a drug that blocks certain mutations that can drive tumour growth.
- The treatment was given alongside chemotherapy.
- Researchers said longer trials are needed to measure survival and determine how long cancer control lasts.
- Cancer Research UK reports about 11,500 pancreatic cancer diagnoses and 10,200 deaths each year in Britain.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.